Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: Capricor - What They Never Told You

Duchenne Cell Therapy Decision Slips to November After FDA Labels New Arm Function Data a Major Amendment

FDA pushed the deramiocel decision to November 22 after classifying Capricor's new 24-month HOPE-3 data as a major amendment to the filing.

Duchenne Cell Therapy Shifts Its Target from the Heart to Arm Function as Decision Date Slips

Duchenne Cell Therapy Shifts Its Target from the Heart to Arm Function as Decision Date Slips

Capricor will amend its deramiocel filing to seek an upper-limb indication, and says the FDA has signaled that the August 22 decision date will move.

US stocks: Capricor shares 77% soar as potential FDA lifeline revives Duchenne drug hopes

US stocks: Capricor shares 77% soar as potential FDA lifeline revives Duchenne drug hopes

Capricor Therapeutics shares surged significantly after the FDA agreed to review new drug data. The company had faced setbacks last month regarding its experimental Duchenne muscular dystrophy treatment. New 24-month data will focus on improving upper limb muscle function for the drug. Analysts view the FDA's willingness to review this…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga Bulls And Bears: Amazon, Microsoft, SpaceX

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.

Duchenne Families Face a Three-Week Wait After FDA Advisers Rejected the Heart Therapy Evidence

FDA advisers voted 9-3 that evidence for dermaicell falls short for Duchenne cardiomyopathy. The FDA decides by August 22. What families should know.

Capricor Therapeutics Q1 Earnings Call Highlights

Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself amid a legal dispute with distribution partner NS Pharma and parent company Nippon Shinyaku. On t

Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Capricor Therapeutics, Inc. (NASDAQ:CAPR) stock soared on Wednesday after the company announced positive topline data from the Phase 3 HOPE-3 trial for its lead cell therapy candidate, deramiocel.

inkl

Read news from The Economist, FT, and more,
with one subscription

Capricor Therapeutics (CAPR) Stock Is Sliding Today: Should Retail Investors Be Worried?

Capricor Therapeutics (CAPR) Stock Is Sliding Today: Should Retail Investors Be Worried?

Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading lower Monday morning after the company reported new data from its exosome-based drug delivery platform. Here’s what investors need to know.

Why Capricor Therapeutics Stock Is Surging Today

Why Capricor Therapeutics Stock Is Surging Today

Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are up Thursday after the company announced progress regarding one of its rare disease therapeutics. The biotech company’s stock jumped 18% immediately following the news.

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday.

Capricor Shares Fall After Topline Results From Mid-Stage COVID-19 Trial

Capricor Shares Fall After Topline Results From Mid-Stage COVID-19 Trial

Capricor Therapeutics Inc (NASDAQ: CAPR) announced topline data from its Phase 2 INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 for hospitalized COVID-19 patients.

Capricor Stops Work On Exosome-mRNA Based COVID-19 Vaccine Candidate

Capricor Stops Work On Exosome-mRNA Based COVID-19 Vaccine Candidate

In its Q4 FY21 earnings press release, Capricor Therapeutics Inc (NASDAQ:

Capricor Therapeutics, Nippon Shinyaku Ink US Pact For Duchenne Muscular Dystrophy Candidate

Capricor Therapeutics, Nippon Shinyaku Ink US Pact For Duchenne Muscular Dystrophy Candidate

Capricor Therapeutics Inc (NASDAQ: CAPR) has partnered with Nippon Shinyaku Co Ltd for the

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

Get all your
news in one place.

100's of premium titles.
One news app.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Amazon.com Inc.

the Bureau of Prisons

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

415,288 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play